Skip to content

US · VRDN · BIOTECHNOLOGY

Viridian Therapeutics, Inc. (VRDN) intrinsic value and stock valuation

$29.96as of 2026-11-21 · Mkt cap 1.9B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Viridian Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VRDN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VRDN’s statements →

Viridian Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02453 viridiantherapeutics.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$70.9M+132.2% 5y CAGRd
20122025
Net income
-$-342.6M
20122025
Free cash flow
-$-276.89M
20122025
Total equity
$722.2M+43.2% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$70.9M$300K$310K$1.77M$2.96M
Operating income-$-363.39M-$-299.04M-$-254.45M-$-134.3M-$-79.73M
Net income-$-342.6M-$-269.95M-$-237.73M-$-129.87M-$-79.41M
EPSd-$-4.04M-$-3.98M-$-5.31M-$-4.05M-$-6.66M
Operating cash flow-$-276.39M-$-232.32M-$-184.17M-$-93.84M-$-54.58M
Capital expenditure-$-490K-$-510K-$-900K-$-800K-$-340K
Free cash flow-$-276.89M-$-232.83M-$-185.07M-$-94.64M-$-54.92M
Total assets$899.4M$742.4M$490.4M$435.1M$203.7M
Total debt$50.7M$21.1M$21.1M$5.26M$1.04M
Net debt-$-161.69M-$-78.5M-$-81.78M-$-150.32M-$-41.26M
Total equity$722.2M$671.6M$442M$395.1M$187.7M
Cash and short-term investments$874.7M$717.6M$477.4M$424.6M$197M
Income statement
20252024202320222021
Revenue$70.9M$300K$310K$1.77M$2.96M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$70.9M$300K$310K$1.77M$2.96M
Research and development expenses$338.9M$238.3M$159.8M$100.9M$56.9M
Selling, general and administrative expenses$95.3M$61.1M$95M$35.2M$25.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$434.2M$299.3M$254.8M$136.1M$82.7M
Cost and expenses$434.2M$299.3M$254.8M$136.1M$82.7M
Interest income$27.4M$32.1M$18.6M$4.92M$320K
Interest expense$4.95M$3.05M$1.85M$490K$0.00
Depreciation and amortization$460K$1.24M$520K$260K$120K
Ebitda-$-337.19M-$-265.66M-$-235.37M-$-129.13M-$-79.29M
Operating income-$-363.39M-$-299.04M-$-254.45M-$-134.3M-$-79.73M
Total other income/expenses, net$20.8M$29.1M$16.7M$4.43M$320K
Income before tax-$-342.6M-$-269.95M-$-237.73M-$-129.87M-$-79.41M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-342.6M-$-269.95M-$-237.73M-$-129.87M-$-79.41M
Weighted average shares outstanding$84.8M$67.9M$44.8M$32.1M$11.9M
Weighted average diluted shares outstanding$84.8M$67.9M$44.8M$32.1M$11.9M
Balance sheet
20252024202320222021
Cash and short-term investments$874.7M$717.6M$477.4M$424.6M$197M
Net receivables$0.00$0.00$100K$100K$450K
Inventory$0.00$0.00$0.00-$-6.62M$0.00
Total current assets$894.2M$738.5M$486.5M$424.6M$200.2M
Property, plant and equipment, net$3.65M$3.44M$3.34M$2.94M$2.06M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.18M$3.94M$3.95M$10.5M$3.55M
Total assets$899.4M$742.4M$490.4M$435.1M$203.7M
Accounts payable$8.68M$2.14M$2.24M$14.2M$2.33M
Short-term debt$750K$510K$840K$610K$520K
Deferred revenue$370K$290K$290K$290K$290K
Total current liabilities$70.7M$47.9M$26.6M$33.4M$13.6M
Long-term debt$49.9M$20.6M$20.2M$4.64M$520K
Deferred revenue, non-current$34.2M$280K$570K$860K$1.15M
Total non-current liabilities$106.6M$22.9M$21.8M$6.68M$2.36M
Capital lease obligations$750K$510K$840K$610K$1.04M
Total liabilities$177.3M$70.8M$48.4M$40M$16M
Common stock$1.02M$810K$540K$410K$240K
Retained earnings-$-1.34B-$-995.86M-$-725.91M-$-488.17M-$-358.3M
Accumulated other comprehensive income (loss)$450K-$-10K$340K-$-390K-$-160K
Total equity$722.2M$671.6M$442M$395.1M$187.7M
Total investments$662.3M$618M$374.5M$269M$154.7M
Total debt$50.7M$21.1M$21.1M$5.26M$1.04M
Net debt-$-161.69M-$-78.5M-$-81.78M-$-150.32M-$-41.26M
Cash flow statement
20252024202320222021
Net income-$-342.6M-$-269.95M-$-237.73M-$-129.87M-$-79.41M
Depreciation and amortization-$-6.76M$540K$520K$260K$120K
Stock-based compensation$44.3M$42.2M$67.2M$19.8M$14.5M
Change in working capital$23M$9.6M-$-9.43M$16M$1.72M
Accounts receivable$0.00$100K$0.00$350K-$-450K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$6.56M-$-70K-$-12.04M$11.5M$1.66M
Net cash provided by operating activities-$-276.39M-$-232.32M-$-184.17M-$-93.84M-$-54.58M
Investments in property, plant and equipment-$-490K-$-510K-$-900K-$-800K-$-340K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-37.56M-$-228.65M-$-94.25M-$-115.13M-$-74.29M
Common stock issued$348.3M$453.7M$125.1M$291.9M$114.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$426.7M$457.7M$225.7M$322.2M$125.3M
Net change in cash$112.8M-$-3.23M-$-52.75M$113.3M-$-3.6M
Cash at end of period$212.4M$99.6M$102.8M$155.6M$42.3M
Operating cash flow-$-276.39M-$-232.32M-$-184.17M-$-93.84M-$-54.58M
Capital expenditure-$-490K-$-510K-$-900K-$-800K-$-340K
Free cash flow-$-276.89M-$-232.83M-$-185.07M-$-94.64M-$-54.92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Viridian Therapeutics, Inc.

        Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

        CEO
        Stephen F. Mahoney
        Employees
        252
        Beta
        0.90

        Explore

        Frequently asked questions

        What is the intrinsic value of Viridian Therapeutics, Inc. (VRDN)?

        InvestorsCraft does not currently publish an intrinsic value for VRDN. How the IC value is calculated.

        Is VRDN undervalued?

        InvestorsCraft does not publish an undervaluation signal for VRDN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.